Last reviewed 2026-04-20 · How we verify

Intranasal Fentanyl

Intranasal Fentanyl, marketed by Columbia University, holds a position in the pain management segment with a key composition patent expiring in 2028. The drug's primary strength lies in its rapid onset of action, making it a preferred option for acute pain relief. The primary risk is the intense competition in the pain management market, which could impact its market share and revenue.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
• Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy Surgeries (PHASE3)
• Pain Control Alternatives in Pediatric Patients With Distal Radius Fractures (PHASE3)
• Intranasal Versus Intravenous Fentanyl For Procedural Analgesia in Preterm Neonates (EARLY_PHASE1)
• Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old) (NA)
• Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room (PHASE2)
• Pain Managment in Preterm Neonates (PHASE2, PHASE3)
• Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.